Belite Bio (BLTE) Competitors $61.85 -0.46 (-0.74%) Closing price 04:00 PM EasternExtended Trading$61.91 +0.06 (+0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE vs. LEGN, ELAN, RGC, RVMD, GRFS, TGTX, NUVL, RYTM, CRSP, and AXSMShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Belite Bio vs. Its Competitors Legend Biotech Elanco Animal Health Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Nuvalent Rhythm Pharmaceuticals CRISPR Therapeutics Axsome Therapeutics Legend Biotech (NASDAQ:LEGN) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Which has higher valuation and earnings, LEGN or BLTE? Belite Bio has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$627.24M12.95-$177.03M-$0.59-74.93Belite BioN/AN/A-$36.14M-$1.36-45.48 Do institutionals & insiders have more ownership in LEGN or BLTE? 70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, LEGN or BLTE? Legend Biotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, indicating that its stock price is 250% less volatile than the S&P 500. Is LEGN or BLTE more profitable? Belite Bio has a net margin of 0.00% compared to Legend Biotech's net margin of -29.95%. Legend Biotech's return on equity of -21.19% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-29.95% -21.19% -13.47% Belite Bio N/A -32.07%-30.91% Do analysts rate LEGN or BLTE? Legend Biotech presently has a consensus price target of $73.33, suggesting a potential upside of 65.87%. Belite Bio has a consensus price target of $96.67, suggesting a potential upside of 56.29%. Given Legend Biotech's higher possible upside, research analysts plainly believe Legend Biotech is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to LEGN or BLTE? In the previous week, Legend Biotech had 10 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Legend Biotech and 2 mentions for Belite Bio. Legend Biotech's average media sentiment score of 1.11 beat Belite Bio's score of -0.50 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative SummaryLegend Biotech beats Belite Bio on 10 of the 15 factors compared between the two stocks. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98B$3.06B$5.70B$9.48BDividend YieldN/A2.37%4.59%3.99%P/E Ratio-45.4820.7327.9019.95Price / SalesN/A321.12442.19102.72Price / CashN/A43.2336.5558.97Price / Book13.108.308.635.90Net Income-$36.14M-$55.19M$3.24B$258.42M7 Day Performance1.41%5.07%3.22%1.94%1 Month Performance3.64%17.61%10.72%12.02%1 Year Performance28.53%7.03%34.94%20.81% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio1.7601 of 5 stars$61.85-0.7%$96.67+56.3%+24.4%$1.98BN/A-45.4810LEGNLegend Biotech3.6979 of 5 stars$42.23+1.5%$73.33+73.7%-26.0%$7.64B$627.24M-71.582,609Positive NewsAnalyst RevisionELANElanco Animal Health3.5435 of 5 stars$14.67-0.8%$16.00+9.1%+13.2%$7.34B$4.44B19.829,000Analyst ForecastAnalyst RevisionRGCRegencell Bioscience0.358 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Gap DownRVMDRevolution Medicines4.5858 of 5 stars$38.42+0.3%$68.91+79.4%-19.8%$7.13B$11.58M-9.61250Positive NewsGRFSGrifols3.426 of 5 stars$10.00+0.6%$10.30+3.0%+27.1%$6.83B$7.81B8.5523,822Upcoming EarningsTGTXTG Therapeutics3.7211 of 5 stars$37.42-1.3%$43.80+17.0%+85.5%$6.02B$329M157.96290Positive NewsNUVLNuvalent3.3157 of 5 stars$82.46-1.1%$119.60+45.0%-2.5%$5.99BN/A-18.7840Analyst ForecastRYTMRhythm Pharmaceuticals3.2498 of 5 stars$88.63-0.6%$91.93+3.7%+76.3%$5.68B$130.13M-31.54140CRSPCRISPR Therapeutics1.7589 of 5 stars$65.33+0.3%$71.75+9.8%+19.1%$5.62B$37.31M-14.45460Analyst ForecastAnalyst RevisionHigh Trading VolumeAXSMAxsome Therapeutics4.7148 of 5 stars$109.68-1.8%$172.33+57.1%+24.2%$5.50B$385.69M-19.01380Analyst Revision Related Companies and Tools Related Companies LEGN Alternatives ELAN Alternatives RGC Alternatives RVMD Alternatives GRFS Alternatives TGTX Alternatives NUVL Alternatives RYTM Alternatives CRSP Alternatives AXSM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLTE) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLTE Stock Alerts